Cargando…

CBP/β-Catenin/FOXM1 Is a Novel Therapeutic Target in Triple Negative Breast Cancer

Background: Triple negative breast cancers (TNBCs) are an aggressive BC subtype, characterized by high rates of drug resistance and a high proportion of cancer stem cells (CSC). CSCs are thought to be responsible for tumor initiation and drug resistance. cAMP-response element-binding (CREB) binding...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ring, Alexander, Nguyen, Cu, Smbatyan, Goar, Tripathy, Debu, Yu, Min, Press, Michael, Kahn, Michael, Lang, Julie E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315782/ https://www.ncbi.nlm.nih.gov/pubmed/30572639 http://dx.doi.org/10.3390/cancers10120525

Ejemplares similares

CBP/Catenin Antagonist Safely Eliminates Drug Resistant Leukemia Initiating Cells
por: Zhao, Yi, et al.
Publicado: (2015)

Small molecule p300/catenin antagonist enhances hematopoietic recovery after radiation
por: Zhao, Yi, et al.
Publicado: (2017)

Differentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic Cancer
por: Manegold, Philipp, et al.
Publicado: (2018)

Nuclear receptor/Wnt beta-catenin interactions are regulated via differential CBP/p300 coactivator usage
por: Ono, Masaya, et al.
Publicado: (2018)

The Mode of Stem Cell Division Is Dependent on the Differential Interaction of β-Catenin with the Kat3 Coactivators CBP or p300
por: Lukaszewicz, Agnes I., et al.
Publicado: (2019)

Fibroblast Growth Factor Receptor-Mediated Activation of AKT-β-Catenin-CBP Pathway Regulates Survival and Proliferation of Murine Hepatoblasts and Hepatic Tumor Initiating Stem Cells
por: Mavila, Nirmala, et al.
Publicado: (2012)

Small molecule inhibition of CBP/catenin interactions eliminates drug resistant clones in acute lymphoblastic leukemia
por: Gang, Eun Ji, et al.
Publicado: (2013)

Functional and genomic analyses reveal therapeutic potential of targeting β-catenin/CBP activity in head and neck cancer
por: Kartha, Vinay K., et al.
Publicado: (2018)

Kinesin family member 23, regulated by FOXM1, promotes triple negative breast cancer progression via activating Wnt/β-catenin pathway
por: Li, Zhi, et al.
Publicado: (2022)

The Transcriptional Coactivator Cbp Interacts with β-Catenin to Activate Gene Expression
por: Takemaru, Ken-Ichi, et al.
Publicado: (2000)

Identification of FOXM1 as a specific marker for triple-negative breast cancer
por: Tan, Yanli, et al.
Publicado: (2018)

SATB2 drives glioblastoma growth by recruiting CBP to promote FOXM1 expression in glioma stem cells
por: Tao, Weiwei, et al.
Publicado: (2020)

Inhibition of CBP/β‐catenin signaling ameliorated fibrosis in cholestatic liver disease
por: Kimura, Masamichi, et al.
Publicado: (2022)

Therapeutic targeting of CBP/β-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin
por: Chan, King Chi, et al.
Publicado: (2015)

Wnt3a/β-Catenin/CBP Activation in the Progression of Cervical Intraepithelial Neoplasia
por: Feng, Dingqing, et al.
Publicado: (2021)

The Anticancer Effects of FDI-6, a FOXM1 Inhibitor, on Triple Negative Breast Cancer
por: Ulhaka, Karan, et al.
Publicado: (2021)

Targeting the CBP/β-Catenin Interaction to Suppress Activation of Cancer-Promoting Pancreatic Stellate Cells
por: Che, Mingtian, et al.
Publicado: (2020)

Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple‐negative breast cancer
por: Yang, Na, et al.
Publicado: (2019)

EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer
por: Ring, Alexander, et al.
Publicado: (2020)

Effect of inhibition of CBP-coactivated β-catenin-mediated Wnt signalling in uremic rats with vascular calcifications
por: Gravesen, Eva, et al.
Publicado: (2018)

Suppression of Tumor Growth, Metastasis, and Signaling Pathways by Reducing FOXM1 Activity in Triple Negative Breast Cancer
por: Dey, Parama, et al.
Publicado: (2020)

Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines
por: Xie, Xuemei, et al.
Publicado: (2023)

The CBP/β-Catenin Antagonist, ICG-001, Inhibits Tumor Metastasis via Blocking of the miR-134/ITGB1 Axis-Mediated Cell Adhesion in Nasopharyngeal Carcinoma
por: Chen, Luo, et al.
Publicado: (2022)

β-Catenin Is Required for the Tumorigenic Behavior of Triple-Negative Breast Cancer Cells
por: Xu, Jinhua, et al.
Publicado: (2015)

Inhibiting β-catenin disables nucleolar functions in triple-negative breast cancer
por: Weeks, Shannon E., et al.
Publicado: (2021)

The β-catenin/CBP-antagonist ICG-001 inhibits pediatric glioma tumorigenicity in a Wnt-independent manner
por: Wiese, Maria, et al.
Publicado: (2017)

Inhibition of β‐catenin/CBP signalling improves airway epithelial barrier function and suppresses CCL20 release
por: Kuchibhotla, Virinchi N. S., et al.
Publicado: (2020)

CBP-mediated Wnt3a/β-catenin signaling promotes cervical oncogenesis initiated by Piwil2
por: Feng, Dingqing, et al.
Publicado: (2020)

β-Catenin/CBP–Dependent Signaling Regulates TGF-β–Induced Epithelial to Mesenchymal Transition of Lens Epithelial Cells
por: Taiyab, Aftab, et al.
Publicado: (2016)

Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes
por: Masuda, Hiroko, et al.
Publicado: (2017)

Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer
por: Ryu, Won-Ji, et al.
Publicado: (2020)

FOXM1 promotes the growth and metastasis of colorectal cancer via activation of β-catenin signaling pathway
por: Yang, Kankan, et al.
Publicado: (2019)

FOXM 1 induces Vasculogenic mimicry in esophageal cancer through β-catenin /Tcf4 signaling
por: Cheng, Lili, et al.
Publicado: (2020)

Selective inhibitor of Wnt/β-catenin/CBP signaling ameliorates hepatitis C virus-induced liver fibrosis in mouse model
por: Tokunaga, Yuko, et al.
Publicado: (2017)

SHP2 Potentiates the Oncogenic Activity of β-Catenin to Promote Triple-Negative Breast Cancer
por: Martin, Elisha, et al.
Publicado: (2021)

The WAVE3/β-catenin oncogenic signaling regulates chemoresistance in triple negative breast cancer
por: Wang, Wei, et al.
Publicado: (2023)

FoxM1 regulates re-annealing of endothelial adherens junctions through transcriptional control of β-catenin expression
por: Mirza, Muhammad K., et al.
Publicado: (2010)

A lignan induces lysosomal dependent degradation of FoxM1 protein to suppress β-catenin nuclear translocation
por: Dong, Guang-zhi, et al.
Publicado: (2017)

RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer
por: Tentler, John J., et al.
Publicado: (2020)

Integrated network analysis identifies hsa-miR-4756-3p as a regulator of FOXM1 in Triple Negative Breast Cancer
por: Gu, Yuanliang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5ej733i1v2a6a07r1a614ojoua